Back to top
more

Argenx (ARGX)

(Delayed Data from NSDQ)

$674.90 USD

674.90
476,278

-15.42 (-2.23%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $675.45 +0.55 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

EXEL or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

EXEL or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?

by Zacks Equity Research

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

Argenx (ARGX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Argenx (ARGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

AZN or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AZN vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.

Zacks Equity Research

Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?

by Zacks Equity Research

PRGO's first-quarter top line is likely to have been impacted by exited businesses and product lines, and unfavorable currency movements.

Zacks Equity Research

Novavax to Report First-Quarter Earnings: Is a Beat in Store?

by Zacks Equity Research

On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.

Zacks Equity Research

BioMarin's First-Quarter Earnings & Sales Beat Estimates

by Zacks Equity Research

BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.

Zacks Equity Research

Is Roche Holding (RHHBY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Roche Holding AG (RHHBY) and argenex SE (ARGX) have performed compared to their sector so far this year.

Zacks Equity Research

Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On CORT's first-quarter 2025 earnings call, investors are likely to focus on the sales performance of its Cushing's syndrome drug, Korlym.

Zacks Equity Research

Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).

Zacks Equity Research

GSK to Report First-Quarter Earnings: Is a Beat in Store?

by Zacks Equity Research

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.

Zacks Equity Research

Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.

Zacks Equity Research

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?

by Zacks Equity Research

Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.

Zacks Equity Research

Can Moderna Keep the Beat Streak Alive This Earnings Season?

by Zacks Equity Research

When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.

Zacks Equity Research

Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.

Zacks Equity Research

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.

Zacks Equity Research

Beam Therapeutics to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

In the absence of any marketed drugs, investors are set to focus on BEAM's pipeline updates when it reports first-quarter 2025 earnings.

Zacks Equity Research

Wall Street Analysts Believe Argenx (ARGX) Could Rally 25.8%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Argenx (ARGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Amicus Therapeutics to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On FOLD's first-quarter 2025 earnings call, investors are likely to focus on the sales of lead drug Galafold and the combo drug, Pombiliti + Opfolda.

Zacks Equity Research

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know

by Zacks Equity Research

INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

Zacks Equity Research

Verastem Oncology to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of any marketed drugs, investors are set to focus on VSTM's pipeline updates when it reports first-quarter 2025 earnings.